Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €3.38 EUR
Change Today -0.101 / -2.90%
Volume 1.0K
GERN On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 1:14 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

geron corp (GERN) Snapshot

Open
€3.44
Previous Close
€3.48
Day High
€3.48
Day Low
€3.38
52 Week High
03/13/15 - €4.21
52 Week Low
05/9/14 - €1.15
Market Cap
533.5M
Average Volume 10 Days
1.2K
EPS TTM
--
Shares Outstanding
157.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GERON CORP (GERN)

geron corp (GERN) Related Businessweek News

No Related Businessweek News Found

geron corp (GERN) Details

Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

42 Employees
Last Reported Date: 03/11/15
Founded in 1990

geron corp (GERN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $656.9K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $381.4K
Executive Vice President of Development and T...
Total Annual Compensation: $396.1K
Executive Vice President of Legal Affairs & H...
Total Annual Compensation: $326.0K
Executive Vice President of Business Developm...
Total Annual Compensation: $367.8K
Compensation as of Fiscal Year 2014.

geron corp (GERN) Key Developments

Geron Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Geron Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of $9,456,000, net loss of $9,315,000 or $0.06 loss per share on license fees and royalties of $537,000 against loss from operations of $8,731,000, net loss of $8,440,000 or $0.06 loss per share on license fees and royalties of $474,000 for the same period a year ago. The increase in interest and other income in 2015 compared to 2014 was due to higher cash and investment balances in 2015.

Geron Corporation Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 05:00 PM

Geron Corporation Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 05:00 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: John A. Scarlett, Chief Executive Officer, President and Director.

Geron Corporation Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Geron Corporation reported unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenues of USD 0.178 million compared to USD 0.225 million a year ago. Net loss was USD 8.947 million compared to USD 9.281 million a year ago. Basic and diluted net loss per share were USD 0.06 compared to USD 0.07 a year ago. Loss from operations was USD 9,011,000 compared to USD 9,275,000 a year ago. Interest and other income was USD 100,000 compared to USD 115,000 for the comparable 2013 period. The decrease in interest and other income for the fourth quarter of 2014, compared to the same period in 2013, primarily reflects the net result of a gain on the sale of excess laboratory equipment in connection with the closure of the company's research laboratory facility in 2013, partially offset by higher interest income due to increased cash and investment balances with the receipt of USD 96.8 million in net cash proceeds from the underwritten public offering completed in February 2014. For the year, the company reported revenues of USD 1.153 million compared to USD 1.283 million a year ago. Net loss was USD 35.670 million compared to USD 38.379 million a year ago. Basic and diluted net loss per share were USD 0.23 compared to USD 0.30 a year ago. Loss from operations was USD 36,312,000 compared to USD 38,958,000 a year ago. Interest and other income was USD 373,000 for 2014 compared to USD 951,000 for 2013. The decrease in interest and other income for 2014 compared to 2013 primarily reflects the net result of a gain on the sale of excess laboratory equipment in 2013, partially offset by higher interest income due to increased cash and investment balances in 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GERN:GR €3.38 EUR -0.101

GERN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biorestorative Therapies Inc $0.40 USD +0.01
BioTime Inc $5.19 USD 0.00
IntelliCell BioSciences Inc $0.0002 USD 0.0001
Neuralstem Inc $1.85 USD +0.09
ReNeuron Group PLC 4.38 GBp -0.275
View Industry Companies
 

Industry Analysis

GERN

Industry Average

Valuation GERN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 502.7x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 383.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GERON CORP, please visit www.geron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.